Table 1.
Baseline characteristics of coronary artery disease (CAD) patients according to the outcome during follow-up
| Characteristics | No cardiovascular event n=1537 | Cardiovascular event n=136 | Association Test |
|---|---|---|---|
| Age, years |
61.2 ± 9.5 |
62.8 ± 10.5 |
p = 0.059 |
| Females |
323 (21 %) |
39 (29%) |
p = 0.050 |
| Acute coronary syndrome |
467 (30 %) |
58 (43 %) |
p = 3.78 10-3 |
| Previous myocardial infarction |
586 (38 %) |
65 (48 %) |
p = 0.028 |
| Number of stenosed coronary arteries |
|
|
|
| one vessel |
438 (29 %) |
21 (15 %) |
|
| two vessels |
479 (31 %) |
43 (32 %) |
p = 1.31 10-3 |
| three vessels |
620 (40 %) |
72 (53 %) |
|
| Body mass index (kg/m2) |
27.7 ± 3.9 |
27.8 ± 3.8 |
p = 0.927 |
| Current smoker |
304 (20 %) |
33 (24 %) |
p = 0.219 |
| Diabetes mellitus |
240 (16 %) |
43 (32 %) |
p = 1.17 10-5 |
| Hypertension |
1151 (75 %) |
105 (77 %) |
p = 0.606 |
| Medications at enrollment |
|
|
|
| Heparin |
521 (34 %) |
55 (40 %) |
p = 0.132 |
| Antiplatelet therapy |
1327 (86 %) |
108 (79 %) |
p = 0.039 |
| Statins |
800 (52 %) |
68 (50 %) |
p = 0.277 |
| Beta-blocker |
1026 (67 %) |
80 (59 %) |
p = 0.072 |
| ACE-inhibitor |
770 (50 %) |
84 (62 %) |
p = 9.41 10-3 |
| Calcium antagonists |
197 (13 %) |
25 (18 %) |
p = 0.085 |
| Total cholesterol (mgdL-1) |
197 ± 45 |
205 ± 51 |
p = 0.038 |
| HDL-cholesterol (mgdL-1) |
49.4 ± 13.5 |
48.1 ± 13.6 |
p = 0.290 |
| Triglyceride (mgdL-1) |
129 (95–182) |
130 (100–183) |
p = 0.143 |
| CRP (mgL-1) |
2.39 (1.02 - 6.14) |
4.59 (1.89 - 11.7) |
p = 8.41 10-6 |
| Fibrin monomers (μmL) |
3.90 (2.64 - 5.33) |
3.32 (2.64 - 5.34) |
p = 0.514 |
| D-dimers (μgmL-1) |
0.34 (0.24 - 0.52) |
0.39 (0.25 - 0.78) |
p = 0.024 |
| t-TAFI (μg mL-1) |
12.0 ± 2.7 |
12.4 ± 2.7 |
p = 0.196 |
| TAFIa/TAFIai (ngmL-1) |
10.48 (8.13 - 13.95) |
11.59 (9.00 - 15.08) |
p = 2.75 10-3 |
| Soluble Tissue factor (pgmL-1) |
158 (124–204) |
159 (124–208) |
p = 0.641 |
| f-TFPI (ngmL-1) |
10.80 (7.61 - 18.89) |
13.46 (9.34 - 25.89) |
p = 7.54 10-3 |
| Creatinine (mgdL-1) |
0.96 ± 1.03 |
1.03 ± 0.29 |
p = 5.59 10-4 |
| Cystatin C (mgL-1) |
0.81 (0.71 - 0.94) |
0.86 (0.72 - 1.08) |
p = 1.28 10-4 |
| sEPCR(ngmL-1) | 114 (93–161) | 110 (91–177) | p = 0.654 |
t-TAFI measures total Thrombin Activating Fibrinolysis Inhibitor in plasma ; TAFIa/TAFIai measures activated TAFI levels in plasma; f-TFPI = free form of tissue factor pathway inhibitor 1.
Categorical variables are presented as n (%), and continuous variables as mean ± SD or median (25th - 75th percentile) for skewed variables (for these variables, tests were performed on log-transformed distribution).